MedTrace Logo

Effect of Immune X on Common Cold Incidence in Healthy Adults

NCT07787130 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-08-26

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:

* Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period?
* Does Immune X affect the number, duration, and severity of common cold events?

Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.

Participants will:

* Take Immune X or placebo daily for 16 weeks during the winter season.
* Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study.
* Record cold symptoms, medications, and other study information using a smartphone application.
* Provide blood and stool samples during the study.

Conditions

  • Common Cold
  • Upper Respiratory Tract Infection (URTI)

Interventions

DIETARY_SUPPLEMENT

Immune X

500 mg Immune X daily as capsules for 16 weeks.

OTHER

Placebo

Matching placebo capsules daily for 16 weeks.

Sponsors & Collaborators

  • CEN Expérimental

    collaborator UNKNOWN

  • Givaudan France Naturals

    lead INDUSTRY

Principal Investigators

  • Carole Perrin, MD · CEN Expérimental

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-04-30
Completion
2027-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07787130 on ClinicalTrials.gov